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Abstract
Background: Women in Nigeria face some of the highest maternal mortality risks in the world. We explore the
benefits and cost-effectiveness of individual and integrated packages of interventions to prevent pregnancy-related
deaths.
Methods: We adapt a previously validated maternal mortality model to Nigeria. Model outcomes included clinical
events, population measures, costs, and cost-effectiveness ratios. Separate models were adapted to Southwest and
Northeast zones using survey-based data. Strategies consisted of improving coverage of effective interventions, and
could include improved logistics.
Results: Increasing family planning was the most effective individual intervention to reduce pregnancy-related
mortality, was cost saving in the Southwest zone and cost-effective elsewhere, and prevented nearly 1 in 5
abortion-related deaths. However, with a singular focus on family planning and safe abortion, mortality reduction
would plateau below MDG 5. Strategies that could prevent 4 out of 5 maternal deaths included an integrated and
stepwise approach that includes increased skilled deliveries, facility births, access to antenatal/postpartum care,
improved recognition of referral need, transport, and availability quality of EmOC in addition to family planning and
safe abortion. The economic benefits of these strategies ranged from being cost-saving to having incremental
cost-effectiveness ratios less than $500 per YLS, well below Nigeria’s per capita GDP.
Conclusions: Early intensive efforts to improve family planning and control of fertility choices, accompanied by a
stepwise effort to scale-up capacity for integrated maternal health services over several years, will save lives and
provide equal or greater value than many public health interventions we consider among the most cost-effective
(e.g., childhood immunization).
Background
Nigeria accounts for 1 in 6 maternal deaths globally. Ap-
proximately 50,000 Nigerian women die each year from
largely preventable pregnancy-related complications
[1,2]. With a maternal mortality ratio (MMR) estimated
at 840 per 100,000 live births, each of the 34 million
women in their reproductive years face a 1 in 23 lifetime
risk of maternal death [1-4]. In recognition of this, the
Nigerian government and its partners have put in con-
siderable efforts to reduce this burden in line with MDG
5 (e.g. providing free healthcare services to pregnant
women, deploying over 4,000 midwives to areas of great-
est need, distributing free contraceptive products etc
[5,6]). Despite these efforts, the challenges are formid-
able and progress towards MDG 5 has been below
expectations [7-9].
There is little debate about the need for an adequate
supply of skilled birth attendants, functional referral
systems, reliable transport, and well-equipped facilities
[9,10]. However, there is little guidance about how to
adapt ideal recommendations to local situations, decide
where initial efforts should be targeted, and design an
effective and efficient plan to scale-up maternal health
services [6,10]. This is further compounded by the re-
gional variations in maternal indices arising from
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manpower (e.g. the MMR in the Southwest and Northeast
zones are 165 and 1,549 per 100,000 live births respect-
ively [9]).
With increasing attention from the Nigerian govern-
ment [5] and other stakeholders [11], this is an oppor-
tune moment for deliberative action. To effectively
leverage international attention that has catapulted
MDG 5 onto the global political agenda, [12] and
catalyze efforts being made from within the country,
identifying evidence-based strategies that consider the
local context is imperative. In this analysis, we synthesize
the best available data, adapt a model of pregnancy
and pregnancy-related morbidity and mortality to the
Nigerian context, and conduct national and regional
analyses that quantify the payoffs from investing in safe
pregnancy and childbirth. Our purpose is to provide
qualitative insight into the most efficient strategies to
meet MDG 5.
Methods
Overview
Country- and region-specific data were synthesized
using a computer-based model that simulates the natural
history of pregnancy and childbirth. Separate models
were adapted to Southwest and Northeast zones using
survey-based data and information about recognition of
the need for referral, access to transport, and appropri-
ate facilities [8,9,13]. Model outcomes include clinical
events (e.g., pregnancies, live births, maternal complica-
tions), measures of maternal mortality (e.g., MMR, pro-
portionate mortality ratio [i.e., proportion of deaths
among women aged 15–45 that are pregnancy-related],
and lifetime risk of maternal death), population out-
comes (e.g., life-expectancy), and costs.
Strategies consisted of increasing the coverage of ef-
fective interventions, and could include improved logis-
tics. Following standard recommendations for economic
evaluation, we calculated incremental cost-effectiveness
ratios, defined as the additional cost of a specific strategy
divided by its additional clinical benefit, compared with
the next least expensive strategy [14]. We considered
interventions with cost-effectiveness ratios of less than
the per capita GDP ($1,170) to be very cost-effective
[2,15]. Sensitivity analyses are conducted to assess the
impact of parameter uncertainty, and Monte Carlo simu-
lation was used to generate the number of per woman
events such as pregnancies, live births, and facility-based
births.
Model
The Global Maternal Health Policy Model is a previ-
ously published computer-based model that simulates
the natural history of pregnancy and pregnancy-related
complications over a woman’s lifetime, and aggregates
outcomes to a population level [16]. Factors modeled
at the individual level include the probability of preg-
nancy (conditional on age, contraceptive use, and clin-
ical history), the probability of spontaneous or induced
abortion, and the risk of direct pregnancy-related com-
plications such as hypertensive disorders, obstructed
labor, hemorrhage, and sepsis. The case fatality rates of
these complications are conditional on the type, sever-
ity and underlying comorbidity. Nonfatal secondary
complications considered include neurological sequelae,
obstetric fistula, severe anemia, and infertility. In
addition to pregnancy-related mortality risk, women
face an annual risk of death from age-specific all-cause
mortality. The model is described in more detail in the
Additional file 1.
Strategies to reduce maternal deaths consist of im-
proving coverage of effective interventions, either indi-
vidually or packaged as integrated services. These
include: reducing the unmet need for contraception;
increased accessibility to safe abortion and post-abortion
care; prevention and treatment of anemia (including
intermittent prevention and treatment of malaria in
pregnancy); and increased availability of intrapartum and
postpartum care. Recognizing that the investments in in-
frastructure required to assure high-quality intrapartum
care will need to happen in phases, stepwise improve-
ments are modeled over time.
The overall impact of interventions results from a re-
duction in the incidence and/or case fatality rate of a
complication. Both mechanisms depend, in part, on ac-
cess to specific services, trained personnel, and quality
of the facilities delivering these services. Therefore, the
model explicitly considers the location of delivery, type
of assistance, access to basic or comprehensive obstet-
rical care, and the ability to overcome barriers around
the timing of delivery (See Figure 1). Delivery setting is
differentiated by provider (e.g., family member, trad-
itional birth attendant [TBA], SBA or no one) and by
site (e.g., home versus facility). Facilities providing basic
EmOC (bEmOC) are assumed to be capable of adminis-
tering injectable antibiotics, oxytocic drugs, and seda-
tives or anti-convulsants, and also conducting assisted
vaginal delivery, removal of placenta and retained pro-
ducts. Facilities capable of comprehensive EmOC
(cEmOC) are able to provide blood transfusion services,
cesarean delivery, and management of advanced shock
in addition to all the aforementioned bEmOC services
[17].
Health facilities in Nigeria are classified as primary,
secondary and tertiary [7]. Primary care facilities (e.g.
Alausa Primary Health Care center, Lagos State) are the
most abundant, but SBAs aren’t always available, and
only few can provide all the services that constitute
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University College Hospital Ibadan, Oyo State), and
most secondary facilities (e.g. General Hospital Calabar,
Cross River State) can provide comprehensive emer-
gency obstetric care, but they are fewer, and are predom-
inantly in urban areas [19]. In adapting the model to the
Nigerian context, we map the current facility structure
on to the model structure described above.
The model is programmed using TreeAge Pro 2009
(TreeAge Software Inc., Williamstown MA) and analyses
conducted using Microsoft Excel 2010 and Visual Basic
for Applications 7 (Microsoft Corp., Redmond WA).
Data and assumptions
Selected model inputs and assumptions are shown in
Table 1 and Table 2. In general, estimates of incidence
and case fatality rates associated with pregnancy-
related complications were obtained from published
data, and a plausible range for sensitivity analysis was
based on systematic review of the literature. Data on
facility births, skilled birth attendants, family planning,
and antenatal care were from country-specific surveys
and government reports (more details in the Add-
itional file 1).
For women delivering outside an EmOC facility, the
probability of a successful referral depended on over-
coming three categories of delays: delay in recognizing
need for referral and being willing to go; delay in
transport to referral facility; and delay in receiving ap-
propriate care at appropriate EmOC facility. Assump-
tions about barriers to successful referral were based
on country reports, published and grey literature, as
well as in-country visits (between March and Decem-
ber 2010) to elicit expert local opinion [19,45-48]. We
conducted an in-country survey of 121 healthcare fa-
cilities and 700 women aged 15–45 (see Additional
file 1) to provide insight into the range of values for
sensitivity analysis [49]. After using the best available
data to parameterize the national and sub-national
models (for Southwest and Northeast zones), key out-
comes were generated and compared to independent
data. Selected results of this exercise are shown in
Table 3, and the procedure used is described in the
Additional file 1.
Figure 1 Critical delays experienced during labor and delivery. The intervention path during labor and delivery (as contained in the model)
shows the location, attendant, and three potential barriers to effective treatment in the event of a complication, including recognition of referral
need, transfer (e.g., transport), and timely quality care in an appropriate EmOC facility [16].
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Selected costs are shown in Table 1. Details of the cost-
ing methodology are included in the Additional file 1.
Costs of delivering interventions and treating maternal
complications were estimated from the United Nations
Population Fund’s (UNPF) Reproductive Health Costing
Tools (RHCT)[21]. Costs associated with personnel (sal-
aries) were from public access databases [52,53]. Drugs
and supply costs were from the United Nations Children
Fund’s (UNICEF) Supply Catalogue [54] and Manage-
ment Sciences for Health (MSH) International Drug
Price Indicator Guide [54,55]. To estimate the costs of
improving transport and scaling up facilities we used
methods previously described [16] and assumptions
from in-country experts. All costs were converted to
2008 U.S. dollars.
Results
Reducing the unmet need for fertility control (preventing,
spacing and limiting births)
Modern contraceptive prevalence rates range from 3.5%
in the Northeast zone (17.6% unmet need) to 21% in
the Southwest zone (19.7% unmet need) [8,9,13]. Redu-
cing the unmet need by 25% to 100% reduced maternal
deaths by 4% to 17% in the Southwest and 3% to 13%
in the Northeast zone (Table 4, see Additional file 1).
Because the unmet need is based on survey-derived
preferences of Nigerian women questioned now, and
the number of desired children remains high, modeling
elimination of the unmet need only reduces the TFR
from 5.9 to 4.9. Anticipating changes to fertility prefer-
ences over time, we conducted a secondary analysis in
which the use of modern contraceptives was increased
by 25% to 50%, corresponding to a contraceptive preva-
lence rate of 34.7% and 59.7%, respectively (Table 4).
The TFR was reduced from 5.9 to 4.4 (25% increase),
and to 2.9 (50% increase). With a contraceptive preva-
lence rate of 59.7%, approximately 1 out of 2 maternal
deaths was prevented. All of the above strategies were
extremely cost-effective with incremental cost-
effectiveness ratios less than $10 per year of life saved.
Additionally, increasing the use of modern contracep-
tives in the model led to a decline in abortion related
deaths (more details in the Additional file 1).
Table 1 Selected data and assumptions on parameters
used in the model (Coverage and costs)
Coverage Baseline (%) [13]
Current use of family planning
￿Any method 14.6
￿Modern methods 9.7
￿Unmet need 20.2
Antenatal care coverage 57.7
Treatment of anemia [20] 54.3
Total skilled delivery 38.9
Facility delivery 35.0
Home delivery with a skilled birth attendant 6.9
Estimates of costs under
current standard of care (2008 US$)
Model input [21]
Family planning
￿Oral contraceptives $13.54
￿Injectable contraceptives $13.51
￿Condoms $11.30
￿Intrauterine device $13.31
￿Female sterilization $23.29
￿Male sterilization $16.46
Pregnancy and delivery or abortion.
￿Antenatal care (four visits)
a $23.75
￿Anemia treatment (based on severity) $0.68-1.02
￿Abortion
−Post-abortion complications $50.73
−Elective abortion $21.87
Delivery
b
￿Home (TBA; SBA) $7.99; $11.53
￿Facility (birthing center; bEmOC; cEmOC) $20.59; $35.00; $46.33
Postpartum care (one visit)
c $7.14
Transportation
d $5.15 - $11.58
Management of complications
e
￿Obstructed labor $23.63 - $109.96
￿Maternal hemorrhage $34.71 - $150.78
￿Puerperal sepsis $39.08 - $83.90
￿Severe pre-eclampsia/eclampsia $73.82 - $116.17
Costs estimates were obtained from the UNFPA Reproductive Health Costing
Model (RHTCM) [21], and WHO CHOICE public databases [22]. bEmOC=Basic
Emergency Obstetric Care; cEmOC=Comprehensive Emergency Obstetric
Care; TBA=Traditional Birth Attendant; and SBA=Skilled Birth Attendant.
Details and methods for converting to 2008 US$ are provided in the
Additional file 1.
a Cost of prenatal care accrue from the following: Drugs (e.g. iron supplements
and folic acid, tetanus toxoid, etc.), tests (blood group, hemoglobin, blood
glucose, pregnancy test, Rapid Plasma Reagin test [syphilis], HIV test,
Urinalysis, etc.), materials needed to safely administer the aforementioned
drugs or conduct the tests, and personnel costs (nurse/midwife, Obstetrician
and Lab technician) for about 4 antenatal visits [21].
b Total cost reflects the skill of the attendant, level of facility, drugs and
supplies. See the Additional file 1 for details.
c Postpartum care includes examination, iron/folate supplement and
counseling. The cost of post partum care accrue from drugs (iron supplements
and folic acid) and personnel costs (nurse/midwife).
d Transportation costs include those incurred from home to a referral facility
(bEmOC or cEmOC), and those incurred between facilities when necessary
[23]. See the Additional file 1 for details. The range for transportation costs
encompasses cost of transport from home to a health facility (birthing center,
bEmOC or cEmOC facility), and between health facilities (birthing center to
bEmOC or cEmOC and bEmOC to cEmOC).
e The range of costs to manage complications reflects varying severity levels
and whether or not management requires a bEmOC or cEmOC facility.
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Figure 2 shows the benefits expected from improving
intrapartum care (upgrades), superimposed with the
additional benefits from reducing the unmet need for
contraception and increased coverage of safe abortion
services. Strategies that improved intrapartum care alone
had higher cost-effectiveness ratios (i.e., least attractive),
reflecting the higher costs required for infrastructure
Table 2 Input parameters for direct complications of
pregnancy and childbirth
Direct complications Estimates Range
Postpartum hemorrhage (PPH)
Incidence and mortality
−PPH, probability of event
(range) [24,25]
0.114 (0.051-0.228)
g
−PPH, probability of morbidity
(range)
b [26-29]
0.008 (0.006-0.010)
−PPH, case fatality rate (CFR) [30-32] 0.010
−PPH, adjusted CFR (range)
a 0.023 (0.007-0.030)
g
Impact of interventions
−PPH, decrease in incidence
(range) [33,34]
c, d
50%, 75%
g (25%-91%)
−PPH, decrease in case fatality
rate (range)
d, e [30,35-41]
75% (60% - 90%)
g
Obstructed labor (OL)
Incidence and mortality
−OL, probability of event
(range) [24,25]
0.047 (0.030-0.074)
g
−OL, probability of morbidity
(range)
b [26-29]
0.022 (0.018-0.026)
−OL, case fatality rate (CFR) [30-32] 0.007
−OL, adjusted CFR (range)
a 0.019 (0.005-0.025)
g
Impact of interventions
−OL, decrease in incidence
(range) [33,34]
d
-
−OL, decrease in case fatality rate
(range)
d, e [30,35-41]
95% (76% - 100%)
g
Hypertensive disorders of pregnancy (HD)
Incidence and mortality
−HD, probability of event
(range) [24,25]
0.035 (0.025-0.05)
g
−HD, probability of morbidity
(range)
b [26-29]
0.001 (0.001-0.001)
−HD, case fatality rate (CFR) [30-32] 0.017
−HD, adjusted CFR (range)
a 0.021 (0.012-0.027)
g
Impact of interventions
−HD, decrease in incidence
(range) [33,34]
d
NA (25%-50%)
−HD, decrease in case fatality rate
(range)
d, e [30,35-41]
59% (45% - 95%)
g
Sepsis
Incidence and mortality
−Probability of event
(range) [24,25]
0.050 (0.043-0.060)
g
−Probability of morbidity
(range)
b [26-29]
0.400 (0.320-0.480)
−Case fatality rate (CFR) [30-32] 0.013
−Adjusted CFR (range)
a 0.028 (0.009-0.036)
g
Table 2 Input parameters for direct complications of
pregnancy and childbirth (Continued)
Impact of interventions
−Decrease in incidence
(range) [33,34]
c, d
25%, 50% (0%-60%)
−Decrease in case fatality rate
(range)
d, e [30,35-41]
90% (63% - 93%)
g
Unsafe abortion (UA)
Incidence and mortality
−UA, probability of event
(range)
f [24,25]
0.128 (0.050-0.250)
−UA, probability of morbidity
(range)
b [26-29]
0.120 (0.096-0.144)
−UA, case fatality rate (CFR) [30-32] 0.003
−UA, adjusted CFR (range)
a 0.009 (0.002-0.012)
Impact of interventions
−UA, decrease in incidence
(range) [33,34]
d
NA (0%-100%)
−UA, decrease in case fatality rate
(range)
d, e [30,35-41]
98%
c (50% - 100%)
a CFRs were adjusted based on complication severity (e.g., life threatening
complications requiring cEmOC) and underlying severity of anemia [42].
b Examples of nonfatal complications include Sheehan’s syndrome from
obstetric hemorrhage, fistula from obstructed labor, neurologic sequelae from
eclampsia, pelvic inflammatory disease (PID).Not shown but included are the
risk of infertility from PID (0.086), and the risk of severe anemia following
obstetric hemorrhage (0.09) [27,43].
c The incidence of sepsis reduced by 50% with SBA and clean delivery in
birthing center, bEmOC, and cEmOC; and reduced by 25% with SBA and clean
delivery at home [34]. Incidence of maternal hemorrhage reduced by
50%–75% depending on expectant versus active management of labor; we
assume for the status quo, all cEmOC facilities provide active management,
50% of bEmOC facilities provide active management, and birthing
centers/health centers provide expectant management only [33].
d For each baseline estimate, sensitivity analysis was conducted across a
plausible range based on literature review; references and assumptions are
documented in the Additional file 1.
e Estimates shown represent average reduction in case fatality rate provided
complications necessitating surgery (e.g., cesarean section), blood transfusion,
intensive hemodynamic support are treated in cEmOC. Obstructed labor is
managed using assisted vaginal delivery with forceps or vacuum and, if
necessary, cesarean section; severe pre-eclampsia and eclampsia treated with
intravenous hydralazine and magnesium sulfate, in addition to induction of
labor or emergency cesarean section when required; sepsis treated with
ampicillin, gentamycin, and metronidazole or equivalent regimen followed by
an 8-d course of intramuscular gentamycin and oral metronidazole (see
Additional file 1 for details) [30,44].
f Incidence of elective abortion is 0.170, all of which are assumed to be unsafe
in the base case. Case fatality rate (CFR) of safe abortion is 0.000006;
representing a 98% reduction in mortality (see Text S1). Incidence of
miscarriage (not shown) is 0.150 [25].
g These ranges were used to assess parameter uncertainty on the incidence
and CFR of direct maternal complications, and effectiveness of interventions
(see Table 6).
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planning and safe abortion had very low cost-
effectiveness ratios (i.e., very attractive), but reduced
mortality by 20.5%. A strategic approach that involves
simultaneous improvement in intrapartum care, family
planning and safe abortion was the most efficient and
associated with incremental cost-effectiveness ratios be-
tween the two aforementioned strategies. Further details
are provided in the Additional file 1.
Table 5 provides robust insight into the importance of
investing in all three domains of family planning, safe
abortion and intrapartum care – any approach that fo-
cuses on only one of these, to the exclusion of the other,
will be less effective and cost-effective. But decision
makers will still need to decide on how to proceed with
such stepwise investments in all three domains. While
these choices will be a function of many contextual fac-
tors, we sought to provide decision makers with infor-
mation on the expected benefits, value and efficiency of
different approaches. We applied a time dimension of
twelve years to the analysis to stacked cohorts, and con-
ducted a stylized exercise to identify scale-up approaches
that would be more and less efficient.
For purposes of generating main themes, and not try-
ing to compare an unlimited number of hypotheticals,
we restricted our approaches to three general options:
1) Approach 1: reduce the unmet need for
contraception and increase access to safe abortion
before investing in improvements in intrapartum
care;
2) Approach 2: improve intrapartum care before
reducing the unmet need for contraception and
increasing access to safe abortion;
3) Approach 3: reduce the unmet need for
contraception and increase access to safe abortion
while also investing in improving intrapartum care.
We used UN population projections for Nigerian
women aged 15–45 years over a 15-year period (from
2006 – 2022) and model projected estimates of annual
probability of mortality, proportionate mortality ratio
and cost [56]. Upon applying data specific for “current
status” to the cohort for 2006 and 2007, our population
projections approximated UN projections (with age-
specific variations in population ranging between −3%
and 1% of UN data), as did our estimate of the number
of maternal deaths each year (48,483 and 49,810 in 2007
and 2008 respectively). Further details about these meth-
ods are provided in the Additional file 1.
We applied model generated probabilities of mortality
and costs to the three approaches described above, scal-
ing the interventions over a 12-year period (from 2011
to 2022), and estimated the number of maternal deaths
averted with each approach. Approach 1 could avert
over 270,000 maternal deaths, while Approach 2 and
Approach 3 could respectively avert over 340,000 and
380,000 maternal deaths over 12 year period (see
Table 5).
Sensitivity analyses
Increasing availability of transportation for deliveries re-
ferred to EmOC facilities (from 30% to 100%) led to a
1% reduction in maternal deaths, and an ICER that ran-
ged between $2,700 and $15,800 per YLS. Similarly, in-
creasing the recognition of referral need during skilled
home deliveries and the quality of care in EmOC facil-
ities in an isolated manner resulted in 3% reduction in
maternal deaths. Providing prenatal care to all pregnant
women was not an attractive single intervention with only
a 3% reduction in maternal deaths (ICER=$3,400 /YLS).
However, if it is assumed to increase the odds of a subse-
quent facility delivery, an additional 5% - 33% of maternal
deaths could be averted (ICER<$800 per YLS). We
assumed that 30% of facility births occurred in centers
that could provide all EmOC services, and that 10% of
these occurred in cEmOC facilities. Shifting all routine
EmOC deliveries to cEmOC facilities was much less effi-
cient (ICER ranged between $2,000 and $8,500 per YLS)
than shifting births to bEmOC centers or birthing centers
with reliable attendance and transport to cEmOC centers
if needed.
Table 3 Model validation (some model outputs being
compared to published estimates)
Maternal indices (National) Estimates Model
output
Maternal mortality rate (per 100,000 live births)
￿Published estimates from WHO [50] 800 800
￿Published estimates from World Bank [2,51] 840 800
Total fertility rate
￿Published estimates from WHO,
World Bank and Nigeria DHS 2008 [2,13,50]
5.7 5.8
Annual number of maternal deaths (modeled estimate)
￿Published estimates from WHO [51] 50,000 53,000
Maternal indices (zonal) Estimates Model
output
Maternal mortality rate (per 100,000 live births)
￿Southwest 165 [9] 170
￿Northeast 1,549 [9] 1,557
Total fertility rate
￿Southwest 4.5 [13] 4.6
￿Northeast 7.2 [13] 7.2
Selected key outcomes from the model being compared to independent data.
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model inputs to limits suggested by empiric evidence
(see Table 2). These inputs include the incidence and
case fatality rates of direct maternal complications, as
well as the effectiveness and cost of maternal interven-
tions (cost were varied between 50% and 100% of the
original inputs: see Tables 1 and 2). While varying these
inputs, we improved the coverage of effective interven-
tions (i.e. we reduced the unmet need for contraception,
increased access to safe abortion and post-abortion care,
as well as access to optimal intrapartum and postpartum
care). In all instances, the increasing availability of these
interventions was cost effective (with ICERs less than
$550 per YLS). Additionally, while there were significant
differences in outcomes (i.e. the absolute number of ma-
ternal deaths, MMR, lifetime risk or maternal death and
proportionate mortality risk: see the Additional file 1),
the relative impacts of the interventions were constant
(except in instances where the effectiveness of the inter-
ventions were altered: see Table 6). Nevertheless, the
Table 4 Changes in maternal health indices, predicted averted deaths and associated costs (or savings) that
accompanied a stepwise reduction in the unmet need for contraception
Maternal Health Index Status quo Primary analysis on
benefits of family planning
Secondary analysis on
benefits of family planning
Reducing the unmet need for
contraception
Increasing use of modern
contraceptive method
by 25% by 50% by 75% by 100% by 25% by 30% by 40% by 50%
National analysis
Prevalence of modern methods of
contraception (average)
a
9.7% 14.8% 19.8% 24.9% 29.9% 34.7% 39.7% 49.7% 59.7%
Reduction in maternal deaths (%) - 5.9% 9.7% 13.5% 17.4% 24.2% 29.1% 39.1% 49.9%
Total fertility rates 5.90 5.60 5.30 5.10 4.90 4.40 4.11 3.55 2.96
Lifetime risk of maternal deaths 1 in 26 1 in 28 1 in 29 1 in 31 1 in 32 1 in 36 1 in 38 1 in 44 1 in 53
Proportionate mortality risk 14% 13% 12% 12% 11% 10% 10% 8% 7%
Maternal deaths averted per 100,000 - 221 367 512 659 897 1,080 1,449 1,814
Additional costs per woman
over lifetime (US$)
$0.00 $2.46 $4.81 $7.18 $9.55 $16.50 $19.84 $26.55 $33.30
Additional cost to cohort over
lifetime (million US$)
b
- $85.26 $166.89 $248.81 $331.02 $527.12 $687.92 $920.56 $1,154.59
Cost effectiveness ratio
(rounding) (US$ per YLS)
- 6.40/YLS 6.50/YLS 6.60/YLS 6.70/YLS 6.90/YLS 7.10/YLS 7.30/YLS 7.60/YLS
Zonal analysis (Southwest zone)
Prevalence of modern methods of
contraception (average)
a
21.0% 24.6% 28.1% 31.7% 35.2% 46.0% 51.0% 61.0% 71.0%
Reduction in maternal deaths (%) - 4.3% 8.5% 12.9% 17.1% 30.2% 36.3% 48.5% 60.8%
Total fertility rates 4.60 4.40 4.20 4.00 3.80 3.20 2.92 2.36 1.80
Lifetime risk of maternal deaths 1 in 128 1 in 134 1 in 140 1 in 147 1 in 155 1 in 184 1 in 201 1 in 249 1 in 328
Proportionate mortality risk 3.1% 2.9% 2.8% 2.7% 2.6% 2.2% 2.0% 1.6% 1.2%
Maternal deaths averted per 100,000 - 34 67 100 133 236 283 378 474
Additional costs per woman
over lifetime (US$)
$0.00 -$0.72 -$1.44 -$2.18 -$2.90 -$5.13 -$6.17 -$8.26 -$10.36
Additional cost to cohort
over lifetime (million US$)
b
- -$4.49 -$9.00 -$13.65 -$18.18 -$32.20 -$38.72 -$51.80 -$64.96
Cost effectiveness ratio
(rounding) (US$ per YLS)
- 8.20/YLS 8.10/YLS 8.10/YLS 8.10/YLS 8.00/YLS 7.90/YLS 7.80/YLS 7.70/YLS
Each step is in comparison with current conditions. YLS=Year or life saved.
a In the model, age specific rates for use of contraception [13] were used in the national analysis, hence the average values are presented above. For the zonal
analysis, average contraceptive rates were used and are presented above.
b Cohort here is made up of the estimated number of women aged 15–45 years old. This amounts to 34.67 million nationally, 6.27 million in Southwest zone, and
3.95 million in the Northeast zone. National figures were derived from the UN World Population Projections [56], and the zonal figures from the 2006 census
(here, the estimated proportion of women aged 15–45 years in each zone [18.5% and 11.7% in the Southwest and Northeast respectively] were applied to the UN
World Population Projection). Additionally, negative costs imply cost savings. Results from the Northeast zonal analysis are in the supplemental text.
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dicted reduction in maternal deaths were largely robust
(see Table 6).
Discussion
Our principal findings are that early intensive efforts to
improve family planning, accompanied by a systematic
stepwise scale-up of intrapartum and emergency obstet-
rical care, could reduce maternal deaths by 75%. Recog-
nizing that a model-based analysis is only as accurate as
the quality of the data that are available, and that our
data limitations were formidable, there are qualitative
insights that appear robust.
First, reducing the unmet need for contraception is
the most effective and cost-effective single intervention
for reducing maternal deaths in the short term. By sim-
ply meeting the total demand for contraception, over
6,500 maternal deaths could be averted each year nation-
wide. Furthermore, it is cost saving in the Southwest
zone (over $18 million in cost-savings), and can provide
funds that could be channeled to other zones with
greater health needs. This strategy would also prevent 1
in 5 deaths from unsafe abortion [16,57]
Second, there is a threshold above which further reduc-
tions in mortality from sole use of contraception are not
possible; integrated interventions that couple family
planning with reliable access to high-quality intrapartum
and emergency obstetrical care are necessary to cross this
threshold. Third, even allowing for considerable variation
in the pace that would be feasible to scale up maternal
Figure 2 Reduction in maternal deaths - incremental benefits of upgrades, family planning and safe abortion. The effect of combining
upgrades, safe abortion and family planning on reducing maternal deaths. SBA=skilled birth attendants, and EmOC=emergency obstetric care.
“Status quo” refers to the model’s estimate of the current total number of maternal deaths per year (48,480), and an average life expectancy of
47 years (compared to 50,000 and 48 years respectively from the published literature). "Adding family planning" means a complete reduction in
unmet need for contraception and "Adding safe abortion" means universal access to safe abortion services. "Upgrades” refers to strategic
increments in SBA supervised home deliveries, recognition of need for referral, facility based deliveries and availability of EmOC centers and
emergency transportation. These increments are from baseline or "Status quo" to 90% -100% (Upgrade 4). The height of each stacked column
represents the estimated reduction in maternal deaths when family planning and safe abortion are added to the upgrades. However, each
color-coded segment represents the contribution from the respective intervention.
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http://www.biomedcentral.com/1471-2458/12/786Table 5 Changes in maternal deaths and incremental costs that could accompany increased coverage of select
maternal interventions
2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 Total
APPROACH 1
Interventions
Reduction in unmet need for contraception 25% 50% 75% 100% 100% 100% 100% 100% 100% 100% 100% 100%
￿Increase in coverage of safe abortion 30% 50% 80% 100% 100% 100% 100% 100% 100% 100% 100% 100%
￿Facility upgrade package ----1 1 2 2 3 3 4 4
Incremental cost (millions) $3.88 $7.91 $12.16 $16.65 $55.27 $56.73 $100.40 $103.00 $151.47 $155.30 $205.89 $210.90 $1,079.55
Maternal deaths averted 2,795 4,912 7,374 9,691 16,969 17,394 25,125 25,736 34,777 35,594 46,639 47,690 274,695
2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 Total
APPROACH 2
Interventions
Reduction in unmet need for contraception ---- - - - - 2 5 % 5 0 % 7 5 % 100%
￿Increase in coverage of safe abortion ---- - - - - 3 0 % 5 0 % 8 0 % 100%
￿Facility upgrade package 1 1 2 2 3 3 4 4 4 4 4 4
Incremental cost (millions) $41.18 $42.28 $89.08 $91.44 $143.63 $147.40 $202.16 $207.39 $205.77 $207.76 $209.61 $211.30 $1,798.99
Maternal deaths averted 7,103 7,284 14,866 15,242 24,183 24,781 35,815 36,686 39,766 42,242 45,124 47,672 340,765
2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 Total
APPROACH 3
Interventions
￿Reduction in unmet need for contraception 25% 25% 50% 50% 75% 75% 100% 100% 100% 100% 100% 100%
￿ Increase in coverage of safe abortion 30% 30% 50% 50% 80% 80% 100% 100% 100% 100% 100% 100%
￿Facility upgrade package 1 1 2 2 3 3 4 4 4 4 4 4
Incremental cost (millions) $42.87 $44.02 $89.20 $91.57 $138.23 $141.86 $186.97 $191.81 $196.73 $201.69 $206.67 $211.66 $1,743.26
Maternal deaths averted 9,664 9,915 19,053 19,540 29,980 30,729 42,414 43,453 44,501 45,552 46,604 47,655 389,060
Select maternal interventions include increased use of modern contraceptives (through reducing unmet need), and safe abortion services, as well as improving
intrapartum care (see text). These interventions are applied in three different ways or “Approaches” to stacked cohorts of women aged 15–45 years over a 12 year
period (from 2011 to 2022). In Approach 1, utilization of modern contraceptives and safe abortion services were gradually maximized prior to improving
intrapartum care; in Approach 2, improvement in intrapartum care was progressively increased to a maximum before the use of modern contraceptives and safe
abortion services were increased; in Approach 3, all three interventions were gradually maximized concurrently.
Table 6 Assessing uncertainty of several biological and nonbiological input parameters
Analysis Predicted reduction in
maternal deaths
Cost effectiveness ratios
(per year of life saved)
Unchanged parameters (i.e. incidences, CFR and effectiveness) 6% - 65% 6.3 - 10.5
Reduced incidences of direct maternal complications 5% - 62% 6.2 - 9.8
Increased incidence of direct maternal complications 6% - 66% 6.4 - 12.0
Reduced CFR of direct maternal complications 6% - 66% 6.3 -10.5
Increased CFR of direct maternal complications 5% - 65% 6.3 - 10.5
Reduced effectiveness of maternal interventions 5% - 58% 6.3 - 10.5
Increased effectiveness of maternal interventions 7% - 72% 6.3 - 10.5
Reduced costs of maternal interventions 6% - 65% 4.2 – 8.4
Increased costs of maternal interventions 6% - 65% 10.4 – 15.1
Estimates used in the sensitivity analysis are as follows: postpartum hemorrhage [reduced incidence=0.051; increased incidence=0.228; reduced CFR=0.007;
increased CFR=0.03; reduced effectiveness of interventions=60%; increased effectiveness of interventions=90%], obstructed labor [reduced incidence=0.03;
increased incidence=0.074; reduced CFR=0.005; increased CFR=0.025; reduced effectiveness of interventions=76%; increased effectiveness of
interventions=100%], hypertensive disorders of pregnancy [reduced incidence=0.025; increased incidence=0.05; reduced CFR=0.012; increased CFR=0.027;
reduced effectiveness of interventions=45%; increased effectiveness of interventions=95%], Sepsis [reduced incidence=0.043; increased incidence=0.06;
reduced CFR=0.009; increased CFR=0.036; reduced effectiveness of interventions=63%; increased effectiveness of interventions=93%]. Additional findings are
contained in the Additional file 1.
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making stepwise improvements in family planning, safe
abortion and intrapartum care will be more effective and
efficient in the long-run than solely focusing on any one
of these alone. A strategy that involved phasic and con-
current improvements in the availability and standard of
EmOC facilities, referral systems, access to skilled birth
attendants, facility deliveries, availability and use modern
contraceptives and access to safe abortion services could
prevent three to four out of five maternal deaths. This
strategy had cost-effectiveness ratios that were a fraction
of Nigeria’s per capita GDP [15].
While our analysis is intended to catalyze actionable
steps, we recognize that decisions in Nigeria will involve
a number of choices on how to proceed with invest-
ments to improve maternal health. Since specific
approaches will need to be designed to be contextually
appropriate for specific settings, we provide generalized
results in a matrix (Table 5) that allows policy makers to
obtain insight into the predicted benefits expected with
a variety of different approaches.
Limitations related to data quality and availability for
informing the natural history parameters in addition to
the assumptions used to build the underlying model
structure have previously been discussed [16]. Data lim-
itations specific to Nigeria are detailed in the Additional
file 1. In addition, data were limited for the frequency of
unsafe abortion, and estimates of unmet need were
based on survey data reflecting women’s desires now,
and not in the future. Additionally, data that were avail-
able and obtained from previous studies, such as many
of the government-sponsored surveys [18,19] each have
their own limitations. While these data may be limited
in quality, they represent the best information available
now. Additionally, the cost inputs are estimates of total
cost, and are agnostic about who bears the cost. How-
ever, our analysis is from a societal perspective aimed at
estimating the total economic (opportunity) cost for the
society. The cost outputs represent costs incurred for a
cohort (which can also be expressed on a ‘per woman’
basis) over the lifetime of the cohort.
We emphasize that the purpose of this analysis was
not to provide precise estimates, but to provide qualita-
tive insight into decisions that will need to be made well
before better data become available, and acknowledge
the necessity for repeated studies as better data become
available. We also acknowledge that other interventions,
outside of those included in this analysis, are likely to
have major benefits on maternal health through indirect
effects (e.g. enactment of policies that improve nutrition
and agriculture, education, transportation and road
networks, security, and equal rights and opportunities).
Albeit outside the health sector, these are critical consid-
erations adjacent to our findings.
Conclusion
Reducing maternal deaths is possible in Nigeria, and several
approaches would be effective, efficient and cost-effective.
Early intensive efforts to improve family planning and con-
trol of fertility choices, accompanied by a stepwise effort to
scale-up capacity for integrated maternal health services
over several years, will save lives and provide equal or
greater value than many public health interventions we
consider among the most cost-effective (e.g., childhood
immunization). With stepwise investments to improve
access to pregnancy-related health services and high-quality
facility-based intrapartum care, more than 75% of maternal
deaths could be prevented. If accomplished over the twelve
years, more than 380,000 women could be saved.
Additional file
Additional file 1: Supplementary materials.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
All authors contributed to the study design, collection and analysis of data,
and writing the paper. All authors approved the final version of the
manuscript.
Funding
Authors would also like to acknowledge the John D. and Catherine T.
MacArthur Foundation grants (#07-8900-00GSS and #10-97002-000-INP). The
funder had no role in the study, design, data collections analysis, decision to
publish or preparation of the manuscript.
Acknowledgements
We are appreciative of assistance from Steve Sweet, Natalie Carvalho,
Zachary Gerson, and Stephen Sy, all of whom helped with calibrating and
debugging the model. We are also appreciative of Dr. Nnena Ihebuzor of the
National Primary Healthcare Development Agency (NPHCDA), and Dr.
Muhammad Ali Pate (Honorable Minister of State for Health and former
Executive Director of the NPHCDA) for the data they shared with us.
Author details
1Center for Health Decision Science, Harvard School of Public Health, 718
Huntington Avenue, 2nd floor, Boston, MA 02115, USA.
2Harvard Global
Health Institute, Harvard University, Cambridge, MA, USA.
3Harvard University
Center for Geographic Analysis, Cambridge, MA, USA.
Received: 19 March 2012 Accepted: 7 September 2012
Published: 14 September 2012
References
1. Hogan MC, et al: Maternal mortality for 181 countries, 1980: a systematic
analysis of progress towards millennium development goal 5. Lancet
2008, 375(9726):p 1609–p 1623.
2. World Bank databank: Nigeria; 2008. Available at http://data.worldbank.org/
country/nigeria Accessed November 24 2010.
3. National Bureau of Statistics, Federal Republic of Nigeria: Annual Abstract of
Statistics; 2009. Available at http://www.nigerianstat.gov.ng. Accessed
August 17, 2011.
4. World Bank (2008) Lifetime risk of maternal death Nigeria; 2010. Available at
http://data.worldbank.org/indicator/SH.STA.MMRT. Accessed November 24.
5. Onyebuchi-Chukwu CO: Nigeria and the millennium development goals:
progress towards 2015.I nA speech presented at the 65th Session of the
United Nations General Assembly to review the Millennium Development Goals.
New York; 2010. Available at http://goo.gl/DZ4s9. Accessed January 2011.
Erim et al. BMC Public Health 2012, 12:786 Page 10 of 11
http://www.biomedcentral.com/1471-2458/12/7866. Onyebuchi Chukwu CO: The action push agenda for the transformation
of the health sector: recent development and the road ahead.A b u j a :
Federal Ministry of Health; 2011:p 4–p5 .
7. Asuzu M: The necessity for a health systems reform in Nigeria. J
Community Med Prim Health Care 2004, 16(1):1–3.
8. Abdullahi MJ: Update/Progress Report on the Implementation of the
Midwives Service Scheme. Abuja: National Primary Healthcare
Development Agency; 2010:p 32–p3 7 .
9. Kale O, et al: Nigerian Health Review. Abuja, Nigeria: Health Reform
Foundation Of Nigeria (HERFON); 2006.
10. Okonofua F: Maternal and Child Health in Nigeria; 2008. Available from:
http://www.nigerianma.org/maternal.ppt.
11. Federal Ministry of Health, N: Health Development Partner Programme Matrix.
Nigeria; 2010. Available at http://fmh.gov.ng/images/stories/documents/
NHDPP-Matrix.xls. Accessed Sept 19, 2011.
12. Hulme D: Reproductive Health and the Millennium Development Goals:
Politics, Ethics. Brooks World Poverty Institute Working Paper Series: Evidence
and an Unholy Alliance; 2009.
13. National Population Commission (NPC) [Nigeria] and ICF Macro (2009):
Nigeria Demographic and Health Survey; 2008. Available at http://www.
measuredhs.com/ pubs/pdf/FR222/FR222.pdf. November 24, 2010.
14. Goldie SJ, Goldhaber-Fiebert JD, Garnett GP: Chapter 18: public health
policy for cervical cancer prevention: the role of decision science,
economic evaluation, and mathematical modeling. Vaccine 2006, 24(3):155.
15. WHO Commission on Macroeconomics and Health: Macroeconomics and
health: investing in health for economic development. Geneva: World Health
Organization; 2001:200 p.
16. Goldie SJ, et al: Alternative strategies to reduce maternal mortality in
India: a cost-effectiveness analysis. PLoS Med 2010, 7(4):p e1000264.
17. UNICEF, WHO, & UNFPA: Guidelines for monitoring the availability and use of
obstetric services. New York, NY 10017, USA: United Nations Children's Fund,
3 UN Plaza; 1997.
18. Government of Nigeria, National Bureau of Statistics: The directory of health
establishments in Nigeria; 2010. Available at http://www.nigerianstat.gov.ng/
nbsapps/nbszip/health.zip. Accessed June 6.
19. National Primary Healthcare Development Agency, Government of
Nigeria: The Midwives Service Scheme (MSS) Baseline Survey Report.
Abuja, Nigeria; 2010. Available at http://nphcda.org/.
20. WHO: Vitamin and Mineral Nutrition Information System (VMNIS).
Nigeria: WHO Global Database on Anaemia; 2009. August 16, 2009;
Available from: http://www.who.int/vmnis/anaemia/data/database/
countries/nga_ida.pdf.
21. Weissman E, Saltner J: Reproductive Health Costing Model, Part 1: Cost per
case. Version 1.1 (Millenuim Project Version). New York NY: UNFPA; 2005.
22. Hutubessy R, WHO-CHOICE, et al: Choosing interventions that are cost-
effective. Health systems performance assessment: debates, methods and
empiricism. Geneva: WHO Editions; 2003:823–835.
23. Borghi JO, et al: Mobilising financial resources for maternal health. Lancet
2006, 368(9545):1457–1465.
24. Henshaw SK, et al: The incidence of induced abortion in Nigeria. Int Fam
Plan Perspect 1998, 24(4):p 156–p 164.
25. Khan KS, et al: WHO analysis of causes of maternal death: a systematic
review. Lancet 2006, 367(9516):1066–1074.
26. Johns B, et al: Estimated global resources needed to attain universal
coverage of maternal and newborn health services. Bull World Health
Organ 2007, 85(4):256–263.
27. Murray CJL, et al: Estimating causes of death: new methods and global and
regional applications for 1990. The global burden of disease 1996, 1:117–200.
28. Ahman E, Dolea C, Shah I: The global burden of unsafe abortion in the year
2000. Geneva: World Health Organization (WHO); 2005. draft working paper.
29. Singh S: Hospital admissions resulting from unsafe abortion: estimates
from 13 developing countries. Lancet 2006, 368(9550):1887–1892.
30. Graham WJ, et al: Maternal and Perinatal Conditions. Disease Control Priorities in
Developing Countries. 2nd edition. New York: Oxford University Press; 2006.
31. Regional Estimates of the Incidence of Unsafe Abortion and Associated
Mortality in 2003. Geneva: World Health Organization; 2004.
32. Shah I, Ahman E: Unsafe abortion: global and regional incidence, trends,
consequences, and challenges. J Obstet Gynaecol Can 2009, 31(12):1149–1158.
33. Dolea C, AbouZahr C, Stein C, Global Burden of Maternal Hemorrhage in
the Year 2000: Evidence and Information for Policy (EIP). Geneva: World
Health Organization; 2003:460.
34. Dolea C, Stein C, Global burden of maternal sepsis in the year: Evidence and
information for policy. Geneva: World Health Organization; 2000.
35. Gulmezoglu AM, et al: WHO multicentre randomised trial of misoprostol
in the management of the third stage of labour. Lancet 2001,
358(9283):689–695.
36. Hofmeyr GJ, Kulier R: External cephalic version for breech presentation at
term. Cochrane Database Syst Rev (Online) 2000, (2):CD000083.
37. Hofmeyr GJ, Hannah ME: Planned caesarean section for term breech
delivery. Cochrane database of systematic reviews (Online) 2001, (1):p.
CD000166.
38. Schuitemaker N, et al: Maternal mortality after cesarean section in The
Netherlands. Acta Obstet Gynecol Scand 1997, 76(4):332–334.
39. Altman D, et al: Do women with pre-eclampsia, and their babies,
benefit from magnesium sulphate? The Magpie trial: a randomised
placebo-controlled trial. Lancet 2002, 359(9321):1877.
40. Duley L, Gulmezoglu AM, Henderson-Smart DJ: Magnesium sulphate and
other anticonvulsants for women with pre-eclampsia. Cochrane Database
Syst Rev (Online) 2003, (2):p CD000025.
41. French L: Prevention and treatment of postpartum endometritis. Curr
Womens Health Rep 2003, 3(4):274.
42. Brabin BJ, Hakimi M, Pelletier D: An analysis of anemia and pregnancy-
related maternal mortality. J Nutr 2001, 131(2):604S.
43. Hu D, et al: The costs, benefits, and cost-effectiveness of interventions to
reduce maternal morbidity and mortality in Mexico. PLoS One 2007,
2(8):e750.
44. Cahuana-Hurtado L, Sosa-Rubi S, Bertozzi S: The application of the mother baby
package reproductive health costing spreadsheet in Morelos: National Institute of
Public Health. Mexico: Division of Health Economics and Policy; 2004.
45. Solagberu B, et al: Pre-hospital care in Nigeria: a country without
emergency medical services. Niger J Clin Pract 2009, 12(1):29.
46. Adesiji G, Dada S, Komolafe S: problems faced by rural people in accessing
health care facilities in Akure north and Akure south local government
areas of Ondo State, Nigeria. J Appl Sci Res 2012, 8(4):2260–2266.
47. The Private Health Sector in Nigeria: An Assessment of Its workforce and
Service Provision. Abuja, Nigeria: Federal Ministry of Health; available at
http://www.fmh.gov.ng/ images/stories/documents/PRIVATE-HEALTH-
SECTOR.pdf.
48. Okaro J, Iyoke C: The Society of Gynaecology and Obstetrics of Nigeria
(SOGON) Plan for Sustainable Reduction in Maternal Mortality: a review.
Afr J Reprod Health 2010, 14(2):139–147.
49. Erim DO, Kolapo UM, Resch SC: A rapid assessment of the availability and
use of obstetric care in Nigerian healthcare facilities. PLoS One 2012, 7(6):
e39555.
50. WHO: Country Health System Fact Sheet 2006 Nigeria; 2006. Available from: http://
www.afro.who.int/index.php?option=com_docman&task=doc_download&gid=
1287&Itemid=2111.
51. Trends in maternal mortality: Estimates developed by WHO, UNICEF, UNFPA
and The World Bank. 2008. Available at http://www.who.int/
reproductivehealth/publications/ monitoring/9789241500265/en/index.html.
52. World Health Organization (WHO) CHOICE: Choosing interventions that are
cost-effective; 2011. cited August 16; Available from: http://www.who.int/
choice/en.
53. International Labour Organization (ILO): Laborsta database. 2010. Available:
http://laborsta.ilo.org/. Accessed 27 Sept. 2010.
54. UNICEF Supply Division; 2010. Available: http://www.supply.unicef.dk/
catalogue/. Accessed 16 August.
55. McFayden JE: International drug price indicator guide. Boston: Management
Sciences for Health; 2005.
56. UN, World Population Prospects: The 2008 Revision. Population Division of the
Department of Economic and Social Affairs of the United Nations Secretariat.
New York: United Nations; 2009.
57. Ahmed S, et al: Maternal deaths averted by contraceptive use: an
analysis of 172 countries. Lancet 2012, 380(9837):111–125. doi:10.1016/
S0140-6736(12)60478-4. ISSN: 0140-6736.
doi:10.1186/1471-2458-12-786
Cite this article as: Erim et al.: Assessing health and economic outcomes
of interventions to reduce pregnancy-related mortality in Nigeria. BMC
Public Health 2012 12:786.
Erim et al. BMC Public Health 2012, 12:786 Page 11 of 11
http://www.biomedcentral.com/1471-2458/12/786